deltatrials
Available NCT04474990

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

VP-VLY-686-3303: Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

Sponsor: Vanda Pharmaceuticals

Conditions Diabetic Gastroparesis Gastroparesis
Interventions Tradipitant
Updated 6 times since 2020 Last updated: Aug 18, 2025

A observational or N/A phase clinical study on Diabetic Gastroparesis and Gastroparesis, this trial is ongoing. The trial is conducted by Vanda Pharmaceuticals and has accumulated 6 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Available

  2. Sep 2024 — Sep 2025 [monthly]

    Available

  3. Jul 2024 — Sep 2024 [monthly]

    Available

  4. Nov 2023 — Jul 2024 [monthly]

    Available

  5. Jan 2021 — Nov 2023 [monthly]

    Available

▶ Show 1 earlier version

  1. Aug 2020 — Jan 2021 [monthly]

    Available

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vanda Pharmaceuticals
Data source: Vanda Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States, Charlotte, United States, Chesterfield, United States, Chevy Chase, United States, Houston, United States, Louisville, United States, Maitland, United States, Nashville, United States, Philadelphia, United States, Plano, United States and 5 more location s